Role of bisphosphonates for the management of skeletal complications and bone pain from skeletal metastases

Supportive Cancer Therapy

Volumn 3, Issue 3, 2006, Pages 143-153

  Costa, Luis ^a   Lipton, Allan ^b   Coleman, Robert E ^c  

^a HOSPITAL DE SANTA MARIA   (Portugal)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Multiple myeloma; Prostate cancer

Indexed keywords

ANALGESIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CORTICOSTEROID; ETIDRONIC ACID; IBANDRONIC ACID; MITOXANTRONE; PAMIDRONIC ACID; PREDNISONE; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; BONE DISEASE; BONE METASTASIS; BONE NECROSIS; BONE PAIN; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RISK; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; FOLLOW UP; HEALTH CARE COST; HUMAN; HYPERCALCEMIA; INCIDENCE; LONG TERM CARE; LUNG CANCER; META ANALYSIS; MORBIDITY; MULTIPLE MYELOMA; OSTEOLYSIS; PAIN ASSESSMENT; PATHOLOGIC FRACTURE; PROSTATE CANCER; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RATING SCALE; REVIEW; RISK FACTOR; SCORING SYSTEM; SOLID TUMOR; SPINAL CORD COMPRESSION; SYSTEMATIC REVIEW; UNITED STATES;

EID: 33745797043     PISSN: 15432912     EISSN: None     Source Type: Journal    
DOI: 10.3816/SCT.2006.n.012     Document Type: Review

References (94)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 55:106-130.
2. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997; 69:1-18.
3. Coleman RE. Bisphosphonates: clinical experience. Oncologist 2004; 9(suppl 4):14-27.
4. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27:165-176.
5. Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80:1588-1594.
6. Jacobs SC. Spread of prostatic cancer to bone. Urology 1983; 21:337-344.
7. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2:584-593.
8. Wilson MA, Calhoun FW. The distribution of skeletal metastases in breast and pulmonary cancer: concise communication. J Nucl Med 1981; 22:594-597.
9. Hortobagyi GN. Bone metastases in breast cancer patients. Semin Oncol 1991; 18(suppl 5):11-15.
10. Weinfurt KP, Li Y, Castel LD, et al. The impact of skeletal-related events on health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2002; 13(suppl 5):180 (Abstract #662P).
11. Oefelein MG, Ricchiuti V, Conrad W, et al. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002; 168:1005-1007.
12. Hansen BH, Keller J, Laitinen M, et al. The Scandinavian Sarcoma Group skeletal metastasis register. Survival after surgery for bone metastases in the pelvis and extremities. Acta Orthop Scand 2004; 75:11-15.
13. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96:879-882.
14. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000; 88:1082-1090.
15. Major PP, Cook R. Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints. Am J Clin Oncol 2002; 25(suppl 1):S10-S18.
16. Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 2003; 21:1404-1411.
17. Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. Ann Stat 1982; 10:1100-1120.
18. Cleeland CS, Ryan KM. Pain assessment global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994; 23:129-138.
19. Body JJ, Diel IJ, Bell R, et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 2004; 111:306-312.
20. Diel IJ, Body J-J, Lichinitser MR, et al. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 2004; 40:1704-1712.
21. American Pain Society. Pain: current understanding of assessment, management and treatments. Available at: http://www.jcaho.org/news+room/ health+care+issues/pain_mono_npc.pdf. Accessed June 3, 2005.
22. Purohit OP, Anthony C, Radstone CR, et al. High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer 1994; 70:554-558.
23. Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005; 23:3314-3321.
24. Body J-J, Diel IJ, Lichinitser MR, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003; 14:1399-1405.
25. Paterson AHG, Powles TJ, Kanis JA, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11:59-65.
26. Body J-J, Diel IJ, Lichinitzer M, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004; 90:1133-1137.
27. Pavlakis N, Schmidt RL, Stockler M. Bisphosphonates for breast cancer (Cochrane review). In: The Cochrane Library. Chichester, UK: John Wiley & Sons Ltd; 2004:1-29.
28. Lipton A. Bisphosphonate therapy for patients with breast cancer. Cur Cancer Ther Rev. In press.
29. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer {published erratum in J Clin Oncol 2004; 22:1351]. J Clin Oncol 2003; 21:4042-4057.
30. Kristensen B, Ejlertsen B, Groenvold M, et al. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 1999; 246:67-74.
31. Heras P, Karagiannis S, Kritikos K, et al. Ibandronate is effective in preventing skeletal events in patients with bone metastases secondary to breast and colorecral carcinoma. Ann Oncol 2004; 15(suppl 3): iii225 (Abstract #853P).
32. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996; 335:1785-1791.
33. Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lyric bone lesions: a randomized, placebo-controlled trial. J Clin Oncol 1999; 17:846-854.
34. Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 1998; 16:2038-2044.
35. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98:1735-1744.
36. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7:377-387.
37. Rosen LS, Coleman RE, Gordon D, et al. Zoledronic acid is superior to pamidronate in patients with breast cancer and bone metastases. Poster presented at: St. Gallen Oncology Conferences: Primary Therapy of Early Breast Cancer 8th International Conference; March 12-15, 2003; St. Gallen, Switzerland.
38. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001; 19:558-567.
39. Hortobagyi GN. Progress in the management of bone metastases: one continent at a time? J Clin Oncol 2005; 23:3299-3301.
40. Carey PO, Lippert MC. Treatment of painful prostatic bone metastases with oral etidronate disodium. Urology 1988; 32:403-407.
41. Kylmala T, Taube T, Tammela TL, et al. Concomitant i.v. and oral clodronate in the relief of bone pain-a double-blind placebo-controlled study in patients with prostate cancer. Br J Cancer 1997; 76:939-942.
42. Heidenreich A, Hofmann R, Engelmann UH. The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol 2001; 165:136-140.
43. Cresswell SM, English PJ, Hall RR, et al. Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer. Br J Urol 1995; 76:360-365.
44. Small EJ, Smith MR, Seaman JJ, et al. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003; 21:4277-4284.
45. Heidenreich A, Elert A, Hofmann R. Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis 2002; 5:231-235.
46. Strang P, Nilsson S, Brandstedt S, et al. The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer. Anticancer Res 1997; 17:4717-4721.
47. Elomaa I, Kylmala T, Tammela T, et al. Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer. Int Urol Nephrol 1992; 24:159-166.
48. Ernst DS, Tannock IF, Winquist EW, et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 2003; 21:3335-3342.
49. Kylmala T, Tammela TL, Lindholm TS, et al. The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer. Ann Chir Gynaecol 1994; 83:316-319.
50. Dearnaley DP, Sydes MR, Mason MD, et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 trial) J Natl Cancer Inst 2003; 95:1300-1311.
51. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94:1458-1468.
52. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004; 100:2613-2621.
53. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003; 21:3150-3157.
54. Conte PF, Rosen LS, Gordon D, et al. Zoledronic acid is superior to pamidronate in patients with breast cancer and multiple myeloma: analysis of patients at high risk for skeletal complications. Poster presented at: 29th European Society for Medical Oncology Congress; October 29-November 2, 2004; Vienna, Austria; Abstract 463PD.
55. Chin JL, Saad F, Gleason DM, et al. Clinical benefit of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer based on history of skeletal complications. Proc Am Soc Clin Oncol 2004; 22:399 (Abstract # 4576).
56. Hirsh V, Tchekmedyian NS, Rosen LS, et al. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Clin Lung Cancer 2004; 6:170-174.
57. Murray R, Chin JL, Saad F, et al. Clinical benefit of zoledronic acid for the prevention of multiple skeletal complications in patients with prostate cancer, based on history of skeletal complications. Poster presented at: 29th European Society for Medical Oncology Congress; October 29-November 2, 2004; Vienna, Austria; Abstract 434P.
58. Brown JE, Thomson CS, Ellis SP, et al. Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 2003; 89:2031-2037.
59. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005; 97:59-69.
60. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62:527-534.
61. Fine PG, Miaskowski C, Paice JA. Meeting the challenges in cancer pain management. J Support Oncol 2004; 2:5-22.
62. Daut RL, Cleeland CS. The prevalence and severity of pain in cancer. Cancer 1982; 50:1913-1918.
63. Portenoy RK, Lesage P. Management of cancer pain. Lancet 1999; 353:1695-1700.
64. Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science 2000; 288:1765-1769.
65. Ripamonti C, Fulfaro F. Pathogenesis and pharmacological treatment of bone pain in skeletal metastases. Q J Nucl Med 2001; 45:65-77.
66. Hoegler D. Radiotherapy for palliation of symptoms in incurable cancer. Curr Probl Cancer 1997; 21:129-183.
67. Abouassaly R, Klein EA. Skeletal complications of metastatic prostate cancer. In: Kantoff P, Saad F, Smith MR, eds. Management of Skeletal Complications of Prostate Cancer and Other Genitourinary Malignancies. CMP Healthcare Media, Oncology Publishing Group; 2004:23-85.
68. Janjan N. Bone metastases: approaches to management. Semin Oncol 2001; 28:28-34.
69. Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases (Cochrane review). In. The Cochrane Library. Chichester, UK: John Wiley & Sons Ltd; 2004: 1-59.
70. Arican A, Icli F, Akbulut H, et al. The effect of two different doses of oral clodronate on pain in patients with bone metastases. Med Oncol 1999; 16:204-10.
71. Conte PF, Giannessi PG, Latreille J, et al. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized, multicenter phase III trial. Ann Oncol 1994; 5:S41-S44.
72. Heim ME, Clemens MR, Queiber W, et al. Prospective randomized trial of dichloromethylene bisphosphonate (clodronate) in patients with multiple myeloma requiring treatment. A multicenter study. Onkologie 1995; 18:439-448.
73. Siris ES, Hyman GA, Canfield RE. Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton. Am J Med 1983; 74:401-406.
74. Smith JA Jr. Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study. J Urol 1989; 141:85-87.
75. Vinholes JJ, Purohit OP, Abbey ME, et al. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol 1997; 8:1243-1250.
76. Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003; 98:962-969.
77. Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339:357-363.
78. Powles T, Paterson S, Kanis JA, et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002; 20:3219-3224.
79. Walker K, Medhurst SJ, Kidd BL, et al. Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain. Pain 2002; 100:219-229.
80. Kohno N, Aogi K, Minami H, et al. Zoledronic acid reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer. Poster presented at: 27th Annual San Antonio Breast Cancer Symposium; December 8-11, 2004; San Antonio, TX; Abstract #3060.
81. Tubiana-Hulin M, Beuzeboc P, Mauriac L, et al. Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bull Cancer 2001; 88:701-707.
82. Lipton A. The role of bisphosphonates in malignant bone disease. Oncology Special Edition 2005; 8:99-103.
83. Biermann WA, Cantor RI, Fellin FM, et al. An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metastatic carcinoma of the breast to bone. Bone 1991; 12:S37-S42.
84. Delea T, McKiernan J, Liss M, et al. Cost of skeletal complications in patients with multiple myeloma [abstract]. Presented at: IXth Annual International Workshop on Multiple Myeloma; May 23-27, 2003; Salamanca, Spain.
85. McKiernan JM, Delea TE, Liss M, et al. Impact of skeletal complications on total medical care costs in prostate cancer patients with bone metastases. Proc Am Soc Clin Oncol 2004; 22:531 (Abstract #6057).
86. Groot MT, Boeken Kruger CGG, Pelger RCM, et al. Costs of prostate cancer, metastatic to the bone, in The Netherlands. Eur Urol 2003; 43:226-232.
87. Delea T, Langer C, McKiernan J, et al. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology 2004; 67:390-396.
88. Delea TE, McKiernan JM, Liss M, et al. Impact of skeletal complications on total medical care costs in lung cancer patients with bone metastases. Proc Am Soc Clin Oncol 2004; 22:533 (Abstract #6064).
89. Ross JR, Saunders Y, Edmonds PM, et al. A systematic review of the role of bisphosphonates in metastatic disease. Health Technol Assess 2004; 8:1-176.
90. Hillner BE, Weeks JC, Desch CE, et al. Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 2000; 18:72-79.
91. Reed SD, Radeva JI, Glendenning GA, et al. Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. J Urol 2004; 171:1537-1542.
92. VA National Center for Patient Safety: Veterans Health Administration. Hip fracture prevention: the benefits of hip protectors. Available at: http://www.va.gov/ncps/safetytopics/fallstoolkit/resources/educational/ hip_fracture_education.ppt. Accessed January 9, 2006.
93. National and regional estimate on hospital use for all patients from the HCUP Nationwide Inpatient Sample (NIS). 2002 National Statistics. Available at: http://www.ahrq.gov/HCUPnet.asp. Accessed January 15, 2006.
94. Yorkshire Cancer Research Network. Breast cancer research newsletter. Available at: www.ycrn.org.uk. Accessed January 30, 2006.